121 related articles for article (PubMed ID: 38622987)
21. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
22. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.
Gårdmark T; Wester K; De la Torre M; Carlsson J; Malmström PU
BJU Int; 2005 May; 95(7):982-6. PubMed ID: 15839918
[TBL] [Abstract][Full Text] [Related]
23. [Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma].
Wu HM; Liu YH; Lin F; Xu FP; Luo DL; Zhang F; Zhuang HG; Luo XL; Wu WL; Lin XT
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):296-9. PubMed ID: 21756821
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma.
Foroozan M; Roudi R; Abolhasani M; Gheytanchi E; Mehrazma M
Pathol Res Pract; 2017 Jun; 213(6):612-618. PubMed ID: 28552539
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
26. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
28. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
[TBL] [Abstract][Full Text] [Related]
29. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
[TBL] [Abstract][Full Text] [Related]
30. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract][Full Text] [Related]
31. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia.
Rajadurai P; Fatt HK; Ching FY
J Gastrointest Cancer; 2018 Jun; 49(2):150-157. PubMed ID: 28124769
[TBL] [Abstract][Full Text] [Related]
33. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
Herawi M; De Marzo AM; Kristiansen G; Epstein JI
Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
35. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
36. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
37. IgG gene expression and its possible significance in prostate cancers.
Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J
Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367
[TBL] [Abstract][Full Text] [Related]
38. Endothelin-1: a predictor of extracapsular extension in clinically localized prostate cancer?
Menard J; Durlach A; Barbe C; Joseph K; Lorenzato M; Azemar MD; Perez T; Birembault P; Staerman F
BJU Int; 2011 Jul; 108(2 Pt 2):E104-9. PubMed ID: 21091977
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland.
O'Kelly F; Elamin S; Cahill A; Aherne P; White J; Buckley J; O'Regan KN; Brady A; Power DG; O'Brien MF; Sweeney P; Mayer N; Kelly PJ
World J Urol; 2014 Aug; 32(4):1067-74. PubMed ID: 24129893
[TBL] [Abstract][Full Text] [Related]
40. GLUT1 expression in high-risk prostate cancer: correlation with
Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
